Scilex Holding to Pay $2 Million to Oramed Pharmaceuticals in Loan Accord

MT Newswires Live09-24

Scilex Holding (SCLX) agreed to pay $2 million to Oramed Pharmaceuticals (ORMP) under a securities purchase agreement.

Of the amount, $1.7 million will applied to the amortization payment due under the $101.9 million senior secured promissory note that Scilex issued to Oramed in 2023, according to a regulatory filing Monday. This note was part of an accord that replaced a previous SPA and debtor in possession term loan facility that Oramed had with Sorrento Therapeutics (SRNE), which Scilex assumed.

The remaining $300,000 is for the purchase of certain warrants to buy Scilex common stock. These warrants were part an agreement providing Oramed with the option to purchase up to 17 million shares of Scilex.

Shares of Scilex fell 9.4% in recent Monday trading, and Oramed rose 3% in

Price: 0.91, Change: -0.09, Percent Change: -9.42

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment